Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 8/20 | 0.55 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.42 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482490 | 0.91 | DRD2 (0.49) | DRD2TBXA2RP2RX3MAPTTHRB | |
| SCHEMBL1482646 | 0.90 | DRD2 (0.53) | DRD2TBXA2RP2RX3DCTPP1RORC | |
| SCHEMBL1483090 | 0.88 | TBXA2R (0.46) | DRD2TBXA2RDCTPP1MAPTGAA | |
| SCHEMBL1482913 | 0.87 | KDM4E (0.48) | DRD2TBXA2RP2RX3 | |
| SCHEMBL1482209 | 0.85 | LPAR2 (0.42) | DRD2TBXA2RP2RX3DCTPP1TP53 | |
| SCHEMBL1482636 | 0.85 | DRD2 (0.52) | DRD2TBXA2RTP53 | |
| SCHEMBL1482809 | 0.84 | DRD2 (0.49) | DRD2TBXA2RP2RX3MAPTTP53 | |
| SCHEMBL1482376 | 0.84 | DRD2 (0.47) | DRD2TBXA2RP2RX3 | |
| SCHEMBL1482410 | 0.82 | KMT2A (0.52) | MAPTNPSR1GAA | |
| SCHEMBL1483030 | 0.82 | DRD2 (0.47) | DRD2TBXA2RP2RX3MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | DRD2 1464/4885TBXA2R 92/4885P2RX3 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.